ReviewWorld journal of gastroenterology2016
Vaccine against Helicobacter pylori: Inevitable approach.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Chitosan Nanoparticles for Enhanced Immune Response and Delivery of Multi-EpitopePharmaceutics · 2025Article
- Adjuvants forVirulence · 2024Review
- T lymphocyte‑related immune response and immunotherapy in gastric cancer (Review).Oncology letters · 2024Review
- Multidrug resistance inFrontiers in microbiology · 2023Review
- Potential Antigenic Candidates for the Development of Peptide-Based Vaccines to Induce Immunization againstInternational journal of molecular sciences · 2022Article
- Host Cell Antimicrobial Responses againstInternational journal of molecular sciences · 2022Review
- The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications.Frontiers in pharmacology · 2022Review
- Aspartate α-decarboxylase a new therapeutic target in the fight againstFrontiers in microbiology · 2022Article
- Protective immunity enhancedFrontiers in immunology · 2022Article
- Oral Administration of aFrontiers in immunology · 2022Article
- Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections.BMC gastroenterology · 2021Article
- Clinical Relevance ofJournal of clinical medicine · 2021Review
- DNA vaccine containingIranian journal of basic medical sciences · 2021Article
- Knowledge, Attitudes and Practices of Adults in the United Arab Emirates Regarding Helicobacter pylori induced Gastric Ulcers and Cancers.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Two Distinct Etiologies of Gastric Cancer: Infection and Autoimmunity.Frontiers in cell and developmental biology · 2021Review
- Gut Microbiota: The Missing Link BetweenFrontiers in endocrinology · 2021Review
- Ethyl acetate extract of Kaempferia parviflora inhibits Helicobacter pylori-associated mammalian cell inflammation by regulating proinflammatory cytokine expression and leukocyte chemotaxis.BMC complementary medicine and therapies · 2020Article
- Outer Membrane Vesicles ofFrontiers in microbiology · 2020Article
- Article
- Optimizing proton pump inhibitors inWorld journal of gastroenterology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over three decades have passed since the discovery of Helicobacter pylori (H. pylori), and yet many questions about its treatment remain unanswered. For example, there is no certainty regarding continued use of current antibiotic therapy against H. pylori. The bad news is that even combined regimens are also unable to eradicate bacterial colonization. The worst problem with H. pylori chemotherapy is that even if we identify the most successful regimen, it cannot eliminate the risk of re-infection. This problem is further complicated by the fact that clinicians have no information as to whether probiotics are useful or not. Moreover, to date, we have no large scale produced vaccine effective against H. pylori. Due to the relatively rapid and abundant dissemination of guidelines globally reported concerning management of gastric cancer prevention and therapeutic regimens, clinicians may choose a vaccine as better effective weapon against H. pylori. Therefore, a radical shift in adopted strategies is needed to guide ultimate decisions regarding H. pylori management. In light of failures in vaccine projects, we should identify better vaccine design targeting conserved/essential genes. The unique character and persistence of H. pylori pose obstacles to making an effective vaccine. Preferably, in developing countries, the best reasonable and logical approach is to recommend prophylactic H. pylori vaccine among children as an obligatory national program to limit primary colonization. Trying to produce a therapeutic vaccine would be postponed until later. In reality, we should not forget to prescribe narrow spectrum antibiotics. In the current review, I draw a route to define the best adopted strategy against this rogue bacterium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.